someone explain telehealth to me like I have not read a paper in years
someone explain telehealth to me like I have not read a paper in years. Searched first, found three threads that contradict each other, hence the post. Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality. Why…
Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.
Same view.
This is the distinction the whole board runs on. Everything else follows from it.
if a clinic will not name the facility, that is your answer
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
shortage status changes and the whole arrangement changes with it
ask which facility, then ask for their testing